This pharmaceutical company declares the 7th indication for its innovative anti-tumor drug!

In recent years, the domestic research and development of PD-1 products has become more and more popular
.
According to statistics, 85 of the 154 PD-1s currently under research in the world are developed or jointly developed by Chinese companies, accounting for 55%
.
But under the fierce research and development boom, the industry has also begun to realize that the global and domestic PD-1 monoclonal antibody research and development track is becoming more and more crowded
.
Regarding PD-1 market space shrinking and prices falling again and again, analysts believe that in the future, pharmaceutical companies will only have more first-mover advantages if they are approved for more indications and further increase production capacity and commercialization capabilities.
Obtain long-term development capabilities
.
It is worth noting that, affected by this, in order to make the product have more market share, the battle of indications among pharmaceutical companies on PD-1 products has begun to become increasingly fierce
.
It is reported that many local companies are accelerating the development of new indications among varieties with relatively high incidence rates such as lung cancer, liver cancer and gastric cancer
.
In a large number of companies, Cinda Bio has always performed very well
.
Recently, Cinda Biotech announced that the National Medical Products Administration (NMPA) has officially accepted the innovative PD-1 inhibitor Daboshu® (sintilimab injection) combined with bevacizumab and chemotherapy for the treatment of transdermal growth factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) treatment failed EGFR gene mutation-positive locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) new indication listing application (sNDA)
.
According to data, Daboshu® is an innovative oncology drug jointly developed by Cinda Biotech and Eli Lilly Pharmaceuticals.
In December 2018, it was officially approved by the National Medical Products Administration
.
Since its approval, Innovent has been conducting clinical trials on "Daboshu".
In addition to the approved classic Hodgkin's lymphoma, it is also rapidly advancing first-line non-squamous non-small cell lung cancer and first-line lung squamous cell carcinoma.
Development of other indications
.
It is understood that the new indication for Cinda Bio's application for marketing is based on a randomized, double-blind, multi-center phase III clinical study (ORIENT-31)-Daboshu® (sintilimab injection) With or without bevacizumab and chemotherapy for locally advanced or metastatic non-squamous NSCLC with EGFR mutations that have failed EGFR-TKI treatment
.
The industry believes that if this indication can be successfully approved, it will bring new options for the treatment of non-squamous NSCLC patients with EGFR-TKI resistance
.
It is worth noting that before, Daboshu® has been declared for marketing for 6 indications, including Daboshu® combined with pemetrexed and platinum-based chemotherapy for epidermal growth factor receptor (EGFR) without systemic treatment First-line treatment for gene mutation-negative and anaplastic lymphoma kinase (ALK)-negative advanced or recurrent non-squamous non-small cell lung cancer ("nsq NSCLC"); combined gemcitabine and platinum-based chemotherapy for inoperable advanced or recurring The first-line treatment of squamous non-small cell lung cancer.
.
.
In this regard, some analysts have also proposed that a series of applications for new indications are fully demonstrating that the exploration of Daboshu® in multiple large cancer indications is continuously gaining Important progress
.
In the future, as the indications of Daboshu® continue to expand, it is expected to bring more revenue contributions to Cinda Biotech
.